https://www.cancerconference.gr/wp-content/uploads/2021/10/voulgarelis-320x320.jpg
Καθηγητής Παθολογικής Φυσιολογίας-Αιματολογίας ΕΚΠΑ, Αναπληρωτής Καθηγητής – Αιματολόγος, Γ.Ν. «Λαϊκό», Αθήνα

Μιχαήλ Βουλγαρέλης


Current Position 

Professor of Hematology, Department of Pathophysiology, School of Medicine, National and Kapodistrian University of Athens (Director: Prof A.G.Tzioufas).  

Board Certification 

1994: Diploma of the Greek Board of Hematology. 

2011: Diploma of the Greek Board of Internal Medicine. 

Academic posts 

1994-1999: Consultant in Hematology, University Hospital “Evgeneidio”, Athens, Greece.  

2000-2005: Lecturer in Hematology, Department of Pathophysiology, National University of Athens Medical School, Greece. 

2005-2010: Assistant Professor in Hematology, Department of Pathophysiology, National University of Athens Medical School, Greece. 

2010-June 2017: Associate Professor of Hematology, Department of Pathophysiology, University of Athens School of Medicine, Greece. 

June 2017-present: Professor of Hematology, Department of Pathophysiology, University of Athens School of Medicine, Greece. 

5/2015-6/2016: Visiting Scientist, Molecular Oncology of Research Institute. Tufts Medical Center, Boston, USA. 

Reviewer  

Reviewer in 23 international scientific journals, 10 of which in the field of Rheumatology and 4 in Hematology, including Annals of the Rheumatic Diseases, Arthritis & Rheumatism, Arthritis Care & Research, Clinical and Experimental Immunology, Blood, American Journal of Hematology, and Leukemia Research. 

Description of research focuses 

Candidate’s research work after his election as a Lecturer is focused on the following directions: 

  1. Molecular study of myelodysplastic syndromes pathogenesis with emphasis:
  2. in the disorder of the expression of transcription factors involved in the differentiation of hematopoietic cells.
  3. the involvement of immune deregulation in medullary deficiency and clonal progression of the disease. Two doctoral dissertations were completed in this direction under the supervision of the candidate.
  4. Clinical and molecular study oflymphoproliferativediseases of patients with Sjogren’s syndrome with emphasis on the treatment of these diseases with immunomodulatory agents and monoclonal antibodies. In this direction two doctoral dissertations were completed under the supervision of the candidate. 
  5. Study of the hematological manifestations of Systemic LupusErythematosus(SLE) with emphasis on the pathophysiological mechanisms of thrombocytopenia in SLE.  
  6. Clinical and molecular study of idiopathichypereosinophilicsyndrome.  
  7. Candidate’s research project at Tufts Medical Center is related to the involvement of AKT kinase in metabolic changes during hypoxia. The findings of this work provide a clear picture of the ability of cellular metabolites to regulate cell signaling, an emerging scientific field that is predicted to have significant applications in the discovery of drugs against cancer and other diseases in the near future.

Doctoral Theses  

Supervision of 6 doctoral theses.  

Member of the advisory committee in 13 doctoral theses  

Research Work 

  1. A.Participation in funded research projects
  2. Study of lymphoma in primarySjogren’ssyndrome. Participation in the BIOMED research project no.BMH4-CT96-0595 (1999). Cooperation in concerted action of the European Community. (Senior Investigator Prof.M.Moutsopoulos). 
  3. Re-assemblydysregulationof IRF-1 transcription factor mRNA. Study on myelodysplastic syndromes and cell lines. PENED Program 10ED263 of GSRT. (Head of M. Voulgarelis). Funding EUR 156,000,000 (2002). 
  4. Study of the transcription factors of the interferon action network in chronicmyelogenousleukemia. Schedule with Κ.Α. : 70/3/5361. (Scientific coordinator: M. Voulgarelis). Financing agent: private individuals through ELKE. Amount: EUR 77 000 (2002). 
  5. The role of GATA-1 transcription factor in normal erythropoiesis andmyelodysplasia.Kapodistrias program. (Scientific coordinator: M. Voulgarelis). Funding organization: National Center for Research and Development (ELKE). Amount: EUR 15000 (20005). 
  6. Dasatinibwith ex vivo evaluation of the peripheral blood mononuclear cell response to the investigational drug for the treatment of of Idiopathic hyperosinophilic syndrome and chronic eosinophilic leukemia: Phase II clinical study (Scientific coordinator: M. Voulgarelis). Funded by the pharmaceutical company Bristol-Myers Squibb, through the ELKE. Amount: EUR 30,000 (2008). In collaboration with the Research Laboratory of Hematology – Institute of Biomedical Research of the Academy of Athens.
    B. Participation in clinical protocols and programs 
  7. Study of the clinical response of patients with Myelodysplastic Syndrome in the administration of monoclonal antibody cA2 anti-tumor necrosis factor-alpha (Infliximab). In collaboration with the Pathological Department ofEuroclinicAthens and the Research Laboratory of the Hematology Clinic of the University of Crete (2003). 
  8. The Jak-2 V617F mutation in women with a history of abortion or stillbirth and no clinical manifestations ofmyeloproliferativedisease: a case control study. In collaboration with the Research Laboratory of Hematology – Institute of Biomedical Research of the Academy of Athens and Wessex Regional Genetics Laboratory, University of Southampton (2008). 
  9. Use of Rituximab inSjögrenssydrome associated lymphoma patients. In collaboration with the Department of Immunology and the Department of Pathological Physiology (2006). 
  10. SPD422-401 protocol titled: A non-invasive, post-approval safety study to continuously monitor the safety results in a group of patients with idiopathicthrombocythemia(ET) exposed to Xagrid in association with other conventional cytoreductive therapies . The protocol is conducted by mek consulting, with the approval of the National Drug organisation and the Scientific Council of Athens General Hospital ‘LAIKO’. 
  11. Myforticstudy CERL080A2420. Member of the Data Monitoring Committee of the aforementioned European Protocol conducted by Novartis.
    Publications:119 

Citations: 6346 

h index: 43